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Abstract: 
There has been a growing link between a history of cannabis use and neurocognitive 
performance in patients with schizophrenia. Fewer neurocognitive deficits may be a marker of 
the superior social cognition needed to obtain illicit substances, or cannabis use may indicate 
a distinct path to schizophrenia with less neurocognitive vulnerability. This study sought to 
determine whether the relationship of cannabis use and executive function exists 
independently of social cognition. Eighty-seven patients with schizophrenia were 
administered measures of social cognition and executive function. Social cognition was 
assessed using the Bell-Lysaker Emotion Recognition Test to measure affect recognition, and 
the Eyes and Hinting Tests to measure theory of mind. Executive function was assessed by 
the Mental Flexibility component of the Delis-Kaplan Executive Functioning Scale. The 
relations between the variables were examined with structural equation modeling. Cannabis 
use positively related to executive function, negatively related to affect recognition, and had 
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no relationship with theory of mind. There were no indirect effects of other illicit substances 
on amount of regular cannabis use. Alcohol use was related to worse affect recognition. The 
relationship between cannabis use and better executive function was supported and was not 
explained by superior social cognition 
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1.0 INTRODUCTION 
To date, both the presence and duration of cannabis use has been linked to better 
neurocognitive functioning in patients with schizophrenia, especially in the domain of 
executive functioning (Potvin et al., 2008; Løberg and Hugdahl, 2009; Schnell et al., 2009; 
Rabin et al., 2011; Yucel et al., 2012). Recent research has also suggested a potential dose-
response, finding that moderate use, as compared to little to no use or heavy use, was 
associated with less cognitive impairment as measured by neurocognitive and metacognitive 
capacity (Schnakenberg Martin et al., 2016). Of note, some studies have failed to replicate the 
finding of less severe cognitive impairment in individuals with schizophrenia and a history of 
cannabis use (Coulston et al., 2007; Mata et al., 2008; Bahorik et al., 2013), possibly due to 
variations in the definition of cannabis use (e.g. focus on a current or past history of use). In 
trying to understand why cannabis use may be related to better cognition, most authors have 
rejected the possibility that cannabis use directly increases cognitive functioning (Solowij and 
Michie, 2007; Løberg et al., 2014; Power et al., 2015). It has been suggested that better 
executive functioning or overall better neurocognition is a marker of a lesser degree of basic 
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biological vulnerability for developing the disorder (Løberg et al., 2014). Cannabis users may 
have developed psychosis through an alternative pathway with less cognitive vulnerability 
and at an earlier age (Myles et al., 2016; Schnakenberg Martin et al., 2016).  
An alternative explanation is that the cannabis-neurocognition relationship is merely a 
reflection of better overall social cognition. It is possible that the ability to obtain and 
maintain illicit substances is facilitated by greater capacities for social cognition and social 
interaction (Solowij and Michie, 2007; Potvin et al., 2008). In this model, the cannabis – 
neurocognition relationship is considered to be attributed to the conceptual similarity (Penn et 
al., 1997; Harvey and Penn, 2010), supported by moderate correlations between these 
functional domains in several studies (Allen et al., 2007; Ventura et al., 2013). In such a 
model, social cognition could be considered a mediator of the relationship between 
neurocognition and general functioning (Schmidt et al., 2011).  
While social cognition may influence overall neurocognition, these two facets of 
cognition are considered independent of one another (Lysaker et al., 2014). Neurocognition 
assesses more generalized abilities of an individual, while social cognition involves noticing 
the intentions of others, as well as understanding and responding to these intentions (Green et 
al., 2005). It has been suggested that social cognition includes at least three core domains: 
affect recognition (emotion processing), theory of mind (ToM), and attributional style/bias 
(Pinkham et al., 2014). ToM can be defined as the ability to infer the intentions, dispositions, 
and beliefs of others (Green and Horan, 2010), while affect recognition includes ratings of 
affects that are displayed in faces or voices. Meta-analyses and reviews report that individuals 
with schizophrenia show deficits in affect recognition, social perception, and ToM (Bora et 
al., 2009; Green and Horan, 2010; Kohler et al., 2010; Savla et al., 2013; Green et al., 2015).  
If the cannabis – neurocognition relationship is attributed to better social cognition, 
cannabis using patients would be expected to have higher capacities for social cognition. 
4 
 
However, for social cognition the findings are inconclusive and scarce. Meijer et al. (2012) 
reported that lifetime cannabis use was associated with better performance on acquired 
knowledge, facial affect recognition, and facial identity recognition in schizophrenia patients 
(Meijer et al., 2012). Social cognition was also found to be higher in schizophrenia patients 
with a history of cannabis use, compared those with little or no use patients (Schnakenberg 
Martin et al., 2016).  A negative effect of cannabis use on performance in a social cognition 
task that involved managing emotions in patients with schizophrenia spectrum disorders has 
also been reported (Sanchez-Torres et al., 2013). Potvin and colleagues (2007) performed an 
fMRI study suggesting that social emotional processing may be less impaired in substance 
using patients (alcohol and/or cannabis) with schizophrenia who demonstrated activation in 
more neural regions associated with social cognition, compared to patients with schizophrenia 
without substance use (Potvin et al., 2007). 
The present study sought to test whether variance in social cognition can explain the 
relationship between one form neurocognition, namely executive function, and cannabis use. 
We chose to look at executive function given it represents the ability to perform the kinds 
complex and demanding cognitive processes required for complex social exchanges.  To 
increase the validity of the assessment of social cognition measures of both ToM and affect 
recognition were included, and stabilized patients were recruited since executive function and 
social cognition may fluctuate in the acute phase of psychosis (Balogh et al., 2014; Helle et 
al., 2014). ToM and affect recognition were included as these factors are most closely related 
to successful interaction with other people. Amount of lifetime regular cannabis use was 
included to test the notion that social cognition may explain better executive function in 
cannabis using patients due to the ability to maintain substance use. To examine the 
interrelationship between executive function, social cognition, and cannabis, in addition to the 
effects of potential confounders such as other illicit drug use, structural equation modeling 
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was used. It was hypothesized that executive function would be positively associated with 
performance on the two measures of Theory of Mind as well as affect recognition. Further, we 
hypothesized that executive function and social cognition would be positively associated with 
amount of lifetime cannabis use and that social cognition would mediate the relationship of 
executive function and cannabis use.  
2. METHODS 
2.1 Design  
This study had a cross-sectional design. Amount of lifetime cannabis use was the 
dependent variable. Executive functioning, age, and other illicit substance use were the 
independent variables and social cognition measures were the mediating variables. 
 
2.2 Participants 
The participants consisted of 87 patients with a schizophrenia diagnosis which was 
confirmed using the Structured Clinical Interview for DSM-IV (SCID) (First et al., 1995). All 
patients were recruited from a VA Medical Center (n = 72, 82.8 %) and a Community Mental 
Health Center (n = 15, 17.2 %). Inclusion criteria were a schizophrenia diagnosis and 
stabilized symptoms defined as no changes in the use of antipsychotics, hospitalization or 
housing within the last 30 days. Exclusion criteria included current substance dependence 
(including cannabis and excluding nicotine) or a chart diagnosis of mental retardation. All 
patients gave informed consent, and received $30 for participating in the study. The study was 
approved by the Institutional Review Board of Indiana University-Purdue University 
Indianapolis. 
 
2.3 Assessments  
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The clinical instruments and tests were administered by clinically trained research 
staff, possessing, at minimum, a Bachelor degree in psychology. The Positive and Negative 
Syndrome Scale (PANSS) (Kay et al., 1987) was used to rate psychotic symptoms. The 
PANSS five-component model of schizophrenia (Bell et al., 1994) was used, and scores for 
the negative, positive, cognitive, excitement and depression components were reported. 
Reliability was checked every second month, by blind ratings of taped PANSS interviews. 
The intraclass correlation coefficients ranged from .80 to .92 for PANSS components. 
Substance use was recorded using items from the Addiction Severity Index (ASI) (McLellan 
et al., 1980; McLellan et al., 1985). The ASI asks participants to report the number of months 
of lifetime use in which they used a substance at least three times a week, and does not 
involve psychological testing or assessment. Substances reported included cannabis, alcohol, 
heroin, methadone, other opiates/analgesics, barbiturates, other 
sedatives/hypnotics/tranquilizers, cocaine, amphetamines, hallucinogens, and inhalants. The 
psychometric properties of the ASI have been assessed and validated for use with individuals 
with serious mental illness (Hodgins and El-Guebaly, 1992; Zanis et al., 1997).  
 
2.4 Measures of executive function and social cognition 
Executive functioning was examined by use of the Delis Kaplan Executive Function 
System (D-KEFS) which is comprised of nine tests designed to assess higher level cognitive 
functioning (Delis et al., 2001). The test battery includes Trail Making, Verbal Fluency, 
Design Fluency, Color-Word Interference, Sorting Test, Twenty Questions, Wording Context, 
Tower Test, and Proverb Test. In an exploratory factor analysis Clark et al. (2010) identified 
two separate components of executive functioning: inhibition/set shifting and mental 
flexibility by using D-KEFS in patients with schizophrenia (Clark et al., 2010). In the present 
study, the mental (cognitive) flexibility component was used as a measure of executive 
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function and more specifically, was considered to reflect one’s capacity to form ideas of how 
stimuli relate to one another (Lysaker et al., 2008). This factor is based on a synthesis of more 
complex executive functioning processes such as concept formation, abstraction, planning and 
initiation of problem-solving behavior (Clark et al., 2010). The following tests loaded on the 
cognitive flexibility factor: Word Context Test (total consecutively correct scaled score), 
Sorting Test Condition 1 (confirmed correct sorts scaled score), Twenty Questions Test (total 
weighted achievement scaled score), and Proverb Test Condition 1 (total achievement free 
inquiry scaled score).  
ToM was examined by using the Eyes Test and Hinting Test. The Eyes Test consists 
of 36 photographs of pairs of men`s and women`s eyes (Baron-Cohen et al., 2001). Each 
photograph was presented one at a time to the participant whose task was to choose between 
four adjectives that could describe the affective or cognitive mental state of the person on the 
photograph. One point was given for each correct answer and it was possible to achieve a total 
score of 36 points. It has been suggested that the Eyes Test measures the ability to infer the 
mental state without drawing inferences about the content (Bora et al., 2009). The Hinting 
Test (Corcoran et al., 1995) consist of 10 short vignettes where two people are interacting. 
The scenarios are read out loud by the examiner, and each is ended by one of the characters 
giving a hint. The participants were required to report the real intended meaning. Each correct 
answer received 2 points. If not answered correctly, the examiner gave a prompt. Participants 
received a score of one when answering correctly after the additional information. It was 
possible to obtain a total score of 20. The test that was used in the present study was a version 
containing items rewritten in American English (Greig et al., 2004). Both the Eyes and 
Hinting Tests have been administered in stabilized outpatients with schizophrenia (Bora et al., 
2006) and have been shown to distinguish between a non-clinical control group and a group 
of individuals with schizophrenia (Scherzer et al., 2012). However, it is useful to use two 
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different ToM tests when aiming to target different content and contexts related to ToM 
(Scherzer et al., 2012).  
Affect recognition was measured by the Bell-Lysaker Emotion Recognition Task 
(BLERT) (Bell et al., 1997; Bryson et al., 1997). The BLERT is an audio-visual affect 
recognition task, designed to evaluate a person’s ability to discriminate between seven affect 
states, based on facial, voice-tonal and upper-body movement cues that are presented on 
video. The participant was seated three feet in front of a 21-inch monitor and shown 21 
vignettes, that each lasted 10 seconds. The emotions that demonstrated by the same actor in 
the vignettes included: happiness, sadness, fear, disgust, surprise, anger, and no emotion. Each 
of the affect states were paired with three monologues, resulting in 21 combinations.  
After each presentation of the vignettes the tape was paused and the participant selected a 
response from the list of seven affects options. It has been demonstrated that the BLERT 
Total score has high categorical stability (weighed k = 0.94) and strong test-retest reliability (r 
=.0.76) in a sample of patients with schizophrenia (Bryson et al., 1997) and the BLERT has 
demonstrated discriminant validity (Bell et al., 1997). For the purpose of this study, we used 
the number of correct responses.  
 
2.5 Statistical analyses 
SPSS version 22 was used for the descriptive analyses (CORP, 2013). Categorical 
variables were presented by number and percentage and continuous variables were presented 
by mean and standard deviations. The analysis of the data was conducted in two phases. First, 
a Pearson correlation (Pearson r; one-tailed) was used to assess bivariate associations between 
the measures of executive function, social cognition (ToM and affect recognition), and 
substance use (cannabis, illicit substance use and alcohol). An illicit substance use variable 
was created that included heroin, methadone, other opiates/analgesics, barbiturates, other 
9 
 
sedatives/hypnotics/tranquilizers, cocaine, amphetamines, and hallucinogens. In addition, 
skewness was analyzed in order to check for normality in the outcome variable, cannabis use, 
before conducting structural equation modeling (SEM). The structural model of the direct and 
indirect relations between predictor variables and the cannabis outcome variable was 
estimated with Mplus 7.3 (Muthén and Muthén, 2008). Cognitive flexibility together with 
covariate variables, such as alcohol and illicit substance use, were specified as exogenous 
variables and the social cognition variables measuring ToM (Hinting and Eyes tests) and 
affective recognition were specified as intermediate variables. In this way, the model 
consisted of both direct and indirect effects. The Maximum Likelihood Robust (MLR) 
estimation was used to account and correct the model for non-normality in the outcome 
variable. Model fit was evaluated according to established guidelines (Kline, 2010; Wang and 
Wang, 2012). First, a tentative model with all parameters set free was estimated, including 
variables such as age and gender. Then, the model was re-estimated after removing relations 
and variables that did not contribute to the model (Jöreskog, 1993). SEM was used to evaluate 
whether social cognition mediated the relationship between executive function and cannabis 
use.  
 
3. RESULTS 
3.1 Sample characteristic  
The sample mean years of age and education were 49.47 (SD = 8.34) and 12.86 (SD = 
1.72), respectively. Seventy-five (86.2%) of the participants were male. The substances that 
were reported with the longest period of use were alcohol, followed by cannabis, cocaine, 
hallucinogens, amphetamine, heroin, opiates, methadone, sedatives and barbiturates. There 
were no reported uses of inhalants. See Table 1 for a total overview of sociodemographic, 
clinical, and cognitive characteristic of the sample.  
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3.2 Bivariate correlations 
See Table 2 for a presentation of correlations among measures of executive function 
(mental flexibility), social cognition (theory of mind and affect recognition), cannabis use, 
illicit substance use, and alcohol use. Overall, cognitive flexibility demonstrated small to 
moderate significant correlations with ToM tasks, affect recognition and cannabis use (p 
<.05), and cannabis use showed small to moderate correlations with ToM tasks, illicit 
substance use and alcohol use (p < .05). 
 
3.3 Structural equation model with both direct and indirect relations 
First, a tentative model with all parameters set free was estimated. A final model was 
estimated after removing age and gender which did not contribute to the first tentative model. 
The final structural model received a satisfactory fit with data (χ2 = 4.11, df = 3, p = .25, CFI 
= 0.99, TLI = 0.94, RMSEA = .065, RMSEACI = .000-.203, RMSEA Close fit p < .05 = .34) 
(Figure 1).  
 
The results showed that cannabis use was significantly positively related to cognitive 
flexibility and negatively related to affect recognition. Figure 1 illustrates that cognitive 
flexibility was also related indirectly with cannabis use via affect recognition. Additionally, 
Figure 1 illustrates a significant relationship between measures of social cognition, finding a 
significant direct effect between the hinting test and affect recognition, as well as between the 
eyes test and affect recognition. Illicit substance use was not related to any of the variables in 
the model, and alcohol negatively related to affect recognition.  
 
4. DISCUSSION 
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In this study, we sought to determine whether a relationship exists between cannabis 
use and better executive functioning independent of social cognition. As predicted, we found 
that persons with greater capacities to form and shift between ideas reported more months of 
cannabis use across their lifetime. Elevated executive function and increased cannabis use was 
not entirely explained, however, by capacities for social cognition, but may be partially 
explained by affect recognition To the contrary, a higher cognitive flexibility score was 
associated with increased affect recognition and decreased cannabis use, and thus affect 
recognition appeared to partially mediate the relationship between cognitive flexibility and 
cannabis use. As expected, executive functioning was significantly related to the social 
cognition measures. There were no indirect effects of other illicit substances on amount of 
cannabis use. Also, increased alcohol use was significantly related to a lower score on the 
affect recognition task.  
Results thus replicate previous findings (Coulston et al., 2007; Schnell et al., 2009; 
Sanchez-Torres et al., 2013; Wobrock et al., 2013). They are consistent with a meta-analysis, 
that found patients with non-affective psychosis who had better executive functioning 
reported more cannabis use (Yucel et al., 2012). Previous findings also suggested that 
enhanced social cognition predicted recency and frequency of cannabis use (Arnold et al., 
2015). While our findings did not assess recency or frequency of use, our findings fail to 
support the connection between social cognition and cannabis use, except for in relation to 
affect recognition, which was associated with a decrease in cannabis use.   
One explanation for the present findings is that the results are inconsistent with the 
idea that the cannabis- neurocognition relationship is driven by enhanced social cognition 
used to obtain illicit substances. Findings, however, did support the notion that patients with 
the greatest amount of regular cannabis use may have a lower basic biological vulnerability 
for psychosis as evidenced by lesser neurocognitive deficits (see e.g. Løberg et al., 2014 for 
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details on this model). It is also possible that increased executive functioning acts as a 
protective factor for those with highest levels of cannabis use. 
Alternatively, it is also possible that individuals with schizophrenia and a history of 
cannabis use may initially have had higher levels of social cognition which was responsible 
for the initiation of cannabis use, but that these abilities decreased with the development of 
psychosis and/or continued cannabis use. This hypothesis cannot be ruled out with the current 
analysis. Further, this hypothesis is supported by the literature which has shown that 
individuals with lifetime cannabis dependence have difficulty determining and discriminating 
facial emotions (Bayrakçı et al., 2015), as well as neural activation patterns during ToM tasks 
that are similar to those at risk for psychosis (Roser et al., 2012).  
Interestingly, our results and this alternative hypothesis also align with recent findings 
that suggest a dose-response relationship in which moderate cannabis use is associated with 
fewer cognitive deficits, as opposed to high and little to no use (Schnakenberg Martin et al., 
2016). While we did not compare groups categorically in regards to their cannabis use,  our 
model indicated that when accounting for affect recognition, a domain of social cognition, 
decreased executive function is associated with increased cannabis use through indirect 
effects of affect recognition. Thus, our findings show support for why heavy cannabis use in 
schizophrenia was observed to be associated with more severe cognitive deficits compared to 
moderate cannabis use.  
Use of other types of illicit substances did not influence the results. Increased alcohol 
use was related to a lower score on the affect recognition test. This is in line with the finding 
that chronic alcohol use may have adverse effects on the ability to recognize affect for 
substance users without psychosis (Kornreich et al., 2003). There could be several 
explanations for this finding that a higher use of alcohol, and also cannabis, are related to 
worse performance on the affect recognition test in the present study. For example, these 
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deficits could have been present before the initiation of substance use or may have been a 
result of extensive use of alcohol and cannabis. Generally, it has been reported that females 
have better social functioning than men (Ochoa et al., 2012). Also, male gender and younger 
age is often associated to substance use (Large et al., 2014); however, in the present sample, 
the majority were men in their late forties and gender and age were not significantly related to 
cannabis use or the social cognition measures.  
In the present study, the BLERT and not the Hinting or Eyes test, was observed to 
have indirect effects on the relationship between executive function and cannabis use. This 
may be reflective of differences between the tasks, rather than the domains being measured. 
For example, the BLERT taps into a more sophisticated system that is relevant to the 
variables at hand. While the BLERT requires judgements be made about the integration of 
language, facial recognition and prosody, the eyes test requires judgements only on visual 
elements and the hinting test only on language. Conceptually, it is also possible that affect 
recognition, as opposed to ToM, is involved in the relationship between executive function 
and cannabis use in that cannabis use may uniquely interfere with one’s ability to integrate 
information as opposed to more automatic processes. This notion is supported by the literature 
in that deficits in emotion processing have been observed in regular cannabis users without 
schizophrenia compared to non-using peers (Gruber et al., 2009; Platt et al., 2010), although 
this pattern of findings has not been consistently observed in schizophrenia (Meijer et al., 
2012). Previous research also failed to detect differences between heavy cannabis users 
without schizophrenia and controls in the Eyes Task but did find that cannabis users required 
additional processing time to correctly identify happy, sad and angry facial expressions (Platt 
et al., 2010). Thus, it is possible that insufficient time was permitted in the standardized 
testing environment to facilitate optimal performance on the BLERT in heavy cannabis users. 
For example, as cannabis use increases, increased or more intense processing time might be 
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required for integration of information and successful emotional expression recognition, 
which is more essential for affect recognition than ToM. Future research is needed to discern 
if there are more sensitive measures of social cognition more relevant to this unique 
relationship.  
There are limitations. The variance explained by the final model is modest and could 
indicate that additional constructs may be involved. Also, the sample composition limits the 
generalization of the findings. Most of the patients were males in their late forties. Recording 
of amount of substance use were done retrospectively, however, studies have shown that self-
report is able to garner accurate information regarding illicit substance use among adults with 
schizophrenia (Van Dorn et al., 2012). It is also important to acknowledge that individuals 
meeting diagnostic criteria, as per the DSM-IV, for current substance dependence were not 
included. Therefore, it is possible that the study findings do not reflect those with active 
substance dependence. Current/recent cannabis and tobacco use were not systematically 
assessed and could both potentially influence neurocognitive performance. Thus, future 
research should consider the roles of these substances as well as the effects of medication, 
education level, years of hospitalization and negative symptoms. Additionally, this study 
evaluated the relationship of executive function to cannabis use and social cognition, and thus 
future work is needed to discern the relationships with other forms of neurocognition, such as 
verbal memory and attention, and other forms of social cognition such as social perception 
and attributional style/bias. Age of cannabis initiation was also unknown in this study, which 
may be important to consider as current literature suggests that cannabis use during 
adolescence may be particularly relevant both to the risk of development of a psychotic illness 
(Moore et al., 2007; Bossong and Niesink, 2010), as well as to the potential degree of 
detriment to executive function (Jockers-Scherübl et al., 2007; Yucel et al., 2012).  
15 
 
In summary, results failed to suggest social cognition has an impact on the positive 
relationship between executive function and cannabis use in patients with schizophrenia. 
Affect recognition was observed to partially mediate this relationship, such that elevated 
executive function was associated with increased affect recognition and decreased cannabis 
use. However, the link between amount of lifetime cannabis use and executive functioning 
could have been explained by other factors such as medication use, education and negative 
symptoms. With replication this work could have clinical implications. For one this 
relationship could indicate better functional prognosis for the cannabis using patients, 
provided they cease using illicit substances (Mullin et al., 2012). These findings may also 
emphasize the importance of developing interventions that target affect recognition, as 
improving affect recognition may have subsequent effects of decreasing cannabis use. 
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Figure 1: Structural model with beta weights describing the magnitudes between executive function, 
alcohol use, social cognition, and cannabis use. 
 
 
Note: Illicit substance use was not included in the figure because it was not related to any other 
variable in the model. Cogn: Flex = Cognitive flexibility component of the Delis Kaplan Executive 
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Function System; Soc. Cogn: Hinting = ToM (theory of mind) measured with the Hinting Test; Soc. 
Cogn: Eyes = ToM measured with the Eyes Test; Soc. Cogn: Aff. Recogn = Affect recognition measured 
with the Bell-Lysaker Emotion Recognition Task; e = error; Cannabis Use, and Alcohol Use are based 
on lifetime months of regular substance use. 
 
Table 1: Sociodemographic, clinical and cognitive data (N = 87) 
 
Characteristic n Percent (%) 
Gender   
Male 75 86.2 
   
Race   
Caucasian 41 47.1 
African American 45 51.7 
Latino 1 1.1 
   
Medications   
Typical antipsychotic medication 10 13.3 
Atypical antipsychotic medication 52 69.3 
Injectable typical antipsychotic 13 17.3 
   
 
Mean 
Standard 
Deviation (SD) 
General Demographics   
Age 49.47 8.34 
Education (years) 12.86 1.72 
Age at first hospitalization 27.31 12.21 
Life hospitalizations (years) 8.30 8.26 
   
PANSS   
Positive
 
16.56 4.42 
Negative 19.62 5.55 
Excitement 7.67 2.50 
Depressive 12.76 3.97 
Cognitive 17.72 4.43 
Total 76.27 14.04 
   
Executive Function   
Cognitive Flexibility 15.50 9.38 
   
Social Cognition   
ToM: Hinting Test 13.06 4.22 
ToM: Eyes Test 21.08 5.39 
Affect Recognition 12.76 3.15 
   
Lifetime Substance Use (months)   
Alcohol 128.45 152.20 
Cannabis 62.09 99.36 
Cocaine 32.40 61.05 
Hallucinogens 8.29 46.67 
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Amphetamine 2.31 9.19 
Heroin 1.51 5.77 
Methadone 1.01 5.88 
Opiate (other) 1.06 6.01 
Sedatives (other) 0.91 5.75 
Barbiturates 0.51 2.46 
Note: PANSS = Positive and Negative Syndrome Scale; ToM = Theory of Mind 
 
 
Table 2 Bivariate (one-tailed) correlations between measures of executive functioning, social 
cognition and substance use  
Item 1 2 3 4 5 6 7 
1. Cognitive Flexibility
 
   1 0.424** 0.379** 0.578** 0.220* 0.041 0.018 
2. Hinting Test  1 0.260* 0.384** 0.190* -0.002 0.078 
3. Eyes Test   1 0.494** 0.193* 0.035 0.028 
4. Affect Recognition
 
   1 .017 -0.069 -0.168 
5. Cannabis Use     1 0.454** 0.372** 
6. Illicit Substance Use      1 0.161 
7. Alcohol Use       1 
Note: * p <  .05; ** p <  .001. 
 
Highlights 
 
 Association between higher executive function and cannabis use was supported. 
 Cannabis use negatively related to affect recognition. 
 Association between executive function and cannabis is independent of current social 
cognition.  
 Other illicit substance use was not related to social cognition or cannabis use. 
